Over the last few years, as I’ve helped people transition from employer group coverage into full Medicare — walking them through their options, helping them choose the right plan, and answering the dozens of questions that naturally come up — one topic has come up again and again: GLP‑1 medications.
Whether it’s Ozempic, Mounjaro, Wegovy, or Zepbound, the question usually sounds like:
“Will Medicare cover this?”
And for a long time, my answer was the same:
“Yes… but only if it’s being prescribed for diabetes.”
That “yes, but…” has been the reality for years. Medicare simply wasn’t allowed to cover GLP‑1s for weight loss or obesity.
But now, for the first time, that answer has changed — and changed again this week.
Instead of “yes, but…”, we finally moved into “yes, and…”
Yes — and Medicare will now cover certain GLP‑1s for weight loss and obesity under a new program starting July 1, 2026.
And with Medicare’s latest announcement, that access will continue through all of 2027.
The Updated Landscape: The GLP‑1 Bridge Is Now the Main Pathway Through 2027
Medicare has officially determined the new GLP‑1 Bridge program will run at least through December 31, 2027. This determination came after CMS decided not to move forward with the planned BALANCE Model for 2027 — a program most beneficiaries had never heard of anyway. Insurers weren’t ready to participate at the required levels, so CMS is keeping the Bridge in place while it gathers more data and evaluates long‑term options.
The Bottom Line
If you’re on Medicare and interested in GLP‑1s for weight loss, the GLP‑1 Bridge is your pathway — starting July 1, 2026, and running at least through the end of 2027.
What the GLP‑1 Bridge Covers
- Wegovy (injection and oral tablet)
- Zepbound
Coverage is specifically for obesity or weight‑related conditions, not diabetes.
Cost to the Beneficiary
A flat $50 monthly copay, regardless of dose. (This copay does not count toward the Part D out‑of‑pocket cap.)
Ready to Use the Program? Here’s How
- Be enrolled in Medicare Prescription Drug Coverage for 2026 or 2027
- This could be either a Medicare Advantage plan that includes prescription drug coverage or a stand-alone Medicare Prescription Drug plan like those paired with Medicare Supplement plans.
- Meet Medicare’s clinical criteria
- BMI thresholds and certain weight‑related conditions. Your doctor will know.
- Your doctor submits a prior authorization
- It goes directly to Medicare’s central processor, not your Part D plan. Your doctor’s office will know exactly how to do this.
- Fill your prescription at a participating pharmacy
- You’ll pay the flat $50 monthly copay.
What Happens After 2027?
It’s anybody’s guess. CMS hasn’t announced the next step yet. The agency will use 2026–2027 data to determine what long‑term Medicare coverage for weight‑loss GLP‑1s should look like. For now, the Bridge is the program — and it’s locked in through 2027.
My guess is that it will be popular with beneficiaries and a hard horse to put back in the barn, increasing the likelihood of Medicare carrying it forward in some fashion beyond 2027.
Why All This Matters
For the first time, Medicare beneficiaries have a multi‑year, stable pathway to access weight‑loss GLP‑1 medications. This removes a lot of uncertainty and gives everyone –beneficiaries, physicians, insurers, and Medicare itself — more time to plan.
If you’re already covered by Medicare, turning 65, transitioning from employer coverage, or already using a GLP‑1, this is something worth keeping on your radar.
What To Do Next: A Simple, Friendly Checklist
- Confirm that you have Part D coverage for 2026 (and you’ll need it for 2027)
- You need active Part D coverage (Medicare Advantage or stand-alone Part D plan) to use the GLP‑1 Bridge.
- Talk with your doctor
- Find out if you meet Medicare’s clinical criteria.
- Have your doctor submit the prior authorization
- They’ll handle the process directly with Medicare.
- Fill your prescription once approved
- Expect a $50 monthly copay.
- Watch for 2028 updates
- CMS will use 2026–2027 data to determine what comes next.
Finally, Some Good News to Share
For several years, the Medicare conversation around GLP‑1s was a steady stream of “yes, but…”
For the first time, we get to say “yes — and here’s how Medicare will help cover it.” Now, with the GLP‑1 Bridge extended through all of 2027, that “yes, and…” sticks around a little longer — and that’s genuinely good news for a lot of people who’ve been waiting for clarity.
After helping so many people navigate this question over the years, it’s nice to finally have a better answer to share.
If there are specific topics you’d like us to address in future issues please drop us a line at 65plus@bbginc.net with your suggestions.